News
Important Only
EU regulator does not recommend approval of Sarepta's muscle disorder gene therapy
July 25 (Reuters) - Europe's medicines regulator did not recommend the approval of Sarepta Therapeutics' SRPT.O gene therapy Elevidys for a type of rare muscular dystrophy, the health agency said on Friday.Reuters
Fri, Jul 25
India-UK trade deal signals Modi's priorities as New Delhi eyes EU, US pacts
Trade deal with UK marks shift in market opennessIndia to cut tariffs on British vehicles, easing protectionismGovernment maintains red lines on agriculture, dairy By Manoj Kumar NEW DELHI, July 25 (Reuters) - India's trade deal with Britain is a sign of New Delhi's new gradual shift to o...Reuters
Fri, Jul 25
First Citizens BancShares Q2 adjusted EPS beats estimates, $4 bln buyback announced
OverviewFirst Citizens BancShares Q2 adjusted EPS beats analyst expectations, per LSEG dataCo announces $4 bln share repurchase plan following $3.5 bln planDiane Morais appointed to Board of DirectorsOutlookCompany announces $4 bln share repurchase plan, which will start upon completion of ongoing $...Reuters
Fri, Jul 25
Subprime consumer lender OneMain's Q2 adjusted EPS beats estimates
OverviewOneMain Holdings Inc Q2 adjusted EPS of $1.45 beats analyst expectations, per LSEG dataThe subprime consumer lender's net income for Q2 rises to $167 mln, up from $71 mln last yearManaged receivables grow 7% yr/yr to $25.2 blnOutlookCompany did not provide specific guidance for future qu...Reuters
Fri, Jul 25
Auto parts supplier Lear beats Q2 revenue estimates
OverviewLear Q2 revenue of $6.0 bln beats analyst expectations, per LSEG dataAdjusted EPS for Q2 exceeds estimates, indicating strong operational performanceCo awarded new seat programs with BMW, Ford, and global EV automakersOutlookLear sees full-year revenue between $22,470 mln and $23,070 mlnComp...Reuters
Fri, Jul 25
Insurance broker Aon Q2 profit rises on strong risk, health unit growth
July 25 (Reuters) - Insurance brokerage firm Aon AON.N reported a higher second-quarter profit on Friday, boosted by strong demand for its risk management and health solutions.WHY IT'S IMPORTANTDespite persistent recession fears and stubborn inflation, spending on insurance has remained resilie...Reuters
Fri, Jul 25
Advanced Health Intelligence Expects US Tariff Related Disruption To Stabilise In Coming Quarter
July 25 (Reuters) - Advanced Health Intelligence Ltd AHI.AX:EXPECTS US TARIFF RELATED DISRUPTION TO STABILISE IN COMING QUARTERTARIFF SCHEDULES INTRODUCED NEAR-TERM UNCERTAINTY, RESULTING IN DELAYS TO TWO OF CO'S SALES PROSPECT INITIATIVESReuters
Fri, Jul 25
PTTEP Announces Partial Sale Of 40% Participating Interest In Two Gulf Of Thailand Projects
July 25 (Reuters) - PTT Exploration and Production PCL PTTEP.BK:PARTIAL DIVESTMENT OF 40% PARTICIPATING INTEREST IN G1/65 AND G3/65 PROJECTSTO TRANSFER PARTICIPATING INTEREST IN PROJECTS IN GULF OF THAILAND TO VALEURA ENERGYReuters
Fri, Jul 25
Goldman Sachs, BNP Paribas say no more rate cuts by the ECB in 2025
By Siddarth S July 25 (Reuters) - Goldman Sachs and BNP Paribas scrapped their forecasts for a September rate cut by the European Central Bank, now expecting no further easing this year after the ECB held rates steady. "We think the (rate cutting) cycle is over, and the next move is ...Reuters
Fri, Jul 25
Apparel retailer Carter's Q2 sales rise, sees tariff impact in H2 FY 25
OverviewCarter's Q2 fiscal 2025 net sales rose 4% to $585 mlnAdjusted EPS of $0.17 missed analyst expectations, per LSEG dataCo returned $38 mln to shareholders via dividends in H1 fiscal 2025OutlookCompany suspends fiscal 2025 guidance due to leadership changes and tariff uncertaintiesCarter...Reuters
Fri, Jul 25
Flagstar Financial's Q2 net loss narrows to $70 mln
OverviewFlagstar Q2 2025 net loss narrows to $70 mln, showing improvement from Q1Company plans to eliminate bank holding company to streamline operationsStrong C&I momentum with new loan originations up 57% from prior quarterOutlookFlagstar expects return to profitability in Q4 2025Company plans...Reuters
Fri, Jul 25
Flagstar Financial Outlook Fy25 Adjusted Loss Per Share $0.40 To $0.35
July 25 (Reuters) - Flagstar Financial Inc FLG.N:OUTLOOK FY25 ADJUSTED LOSS PER SHARE $0.40 TO $0.35OUTLOOK FY25 NII $1700 MILLION TO $1750 MILLIONOUTLOOK FY26 NII $2,250 – $2,300 MILLIONFY2025 EARNINGS PER SHARE VIEW $-0.30 -- LSEG IBES DATASource text: [ID:n0000910073-25-000105]Further company cov...Reuters
Fri, Jul 25
Immunitybio Reports 60% Increase In Revenue In Q2 2025
July 25 (Reuters) - Immunitybio Inc IBRX.O:IMMUNITYBIO REPORTS 60% INCREASE IN REVENUE IN Q2 2025, WITH YEAR-TO-DATE SALES OF $43 MILLION AND 246% UNIT GROWTH SINCE J-CODE WITH REGULATORY UPDATESIMMUNITYBIO INC - Q2 2025 REVENUE $26.4 MILLIONIMMUNITYBIO INC - UK MHRA APPROVES MARKETING AUTHORIZATION...Reuters
Fri, Jul 25
Flagstar Financial, Inc. Reports Second Quarter 2025 Net Loss Attributable To Common Stockholders Of $0.19 Per Diluted Share
July 25 (Reuters) - Flagstar Financial Inc FLG.N:FLAGSTAR FINANCIAL, INC. REPORTS SECOND QUARTER 2025 NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $0.19 PER DILUTED SHARE AND ADJUSTED NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS OF $0.14 PER DILUTED SHAREReuters
Fri, Jul 25
